BioCentury
ARTICLE | Clinical News

Karyopharm reports Phase II selinexor data

May 16, 2015 1:13 AM UTC

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced preliminary results from two Phase II trials of selinexor ( KPT-330), its first-in-class oral selective inhibitor of nuclear export (SINE) protein exportin 1 ( XPO1; CRM1). Data from both studies were released in abstracts ahead of the American Society of Clinical Oncology (ASCO) meeting.

Karyopharm fell 9% on Thursday, the first trading day after the abstracts were released, and shed $2.02 to $24.81 on Friday. Karyopharm EVP and CFO Justin Renz said he was "very surprised" by the investor reaction. ...